NCT03848507View on ClinicalTrials.gov

Impact of Hyperoncotic Albumin to Support Blood Loss Replacement

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

February 12, 2020

Study Completion Date

February 18, 2020

Conditions
Blood Loss, SurgicalFluid Retention
Interventions
DRUG

albumin 20%

Intravenous administration of 20% albumin during cystectomy

Trial Locations (1)

3010

Patrick Wuethrich, Department of Anaesthesiology and Pain Therapy, University Hospital Bern Inselspital Bern, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03848507 - Impact of Hyperoncotic Albumin to Support Blood Loss Replacement | Biotech Hunter | Biotech Hunter